dr. backes on safety profile of lenvatinib and weekly paclitaxel in endometrial cancer
Published 4 years ago • 122 plays • Length 0:55Download video MP4
Download video MP3
Similar videos
-
1:14
dr. backes on rationale for lenvatinib and weekly paclitaxel in endometrial cancer
-
0:53
dr. backes on next steps for lenvatinib and weekly paclitaxel in endometrial cancer
-
1:01
dr. backes on the film trial in endometrial cancer
-
1:32
dr. makker on safety signals with lenvatinib and pembrolizumab in endometrial cancer
-
0:52
investigating toxicities with lenvatinib plus paclitaxel in ovarian and endometrial cancers
-
1:08
evaluating the benefits of lenvatinib and paclitaxel in recurrent gynecologic cancers
-
0:52
dr. zamarin on lenvatinib plus pembrolizumab in endometrial cancer
-
1:39
dr. makker on synergy between lenvatinib and pembrolizumab in endometrial cancer
-
7:26
standard frontline therapy for endometrial cancer
-
0:56
dr. backes on quality of life with parp inhibitors in ovarian cancer
-
1:30
dr. backes on the utility of sentinel lymph node mapping in cervical cancer
-
7:15
rebastinib plus paclitaxel shows encouraging anti-tumor activity in endometrial cancer
-
1:18
dr. backes on treatment selection with parp inhibitors in ovarian cancer
-
1:21
dr. westin on remaining challenges in endometrial cancer
-
1:21
phase iii trial of denosumab for breast cancer risk reduction in brca1 carriers
-
1:59
dr. cohen on lenvatinib in first- or second-line thyroid cancer
-
1:00
precision oncology in endometrial cancer
-
1:11
dr. backes discusses parp inhibitor combinations in ovarian cancer
-
0:34
pembrolizumab plus enfortumab vedotin for bladder cancer